Sponsored Content by BenchlingReviewed by Ify IsiborJul 13 2026
From initial developability simulations to safety forecasting, researchers are advancing swiftly in antibody R&D with AI – and the initial outcomes are in.
At Benchling’s Nordic Digital Science and Innovation Day, executives in biologics R&D from Ferring, Lundbeck, Novo Nordisk, and Symphogen convened to discuss how AI is currently used, its limitations, and the prerequisites for realizing its full potential. The central inquiry: How prepared is the sector for the ensuing phase of innovation in antibody discovery?
Image Credit: Benchling
About Benchling
Benchling makes biotech research and development faster and more collaborative. Biotechnology has the potential to solve humanity’s most pressing challenges, such as disease, renewable energy, clean water, and hunger. The brightest minds are working on these problems but they are equipped with archaic tools. We aspire to fix this and increase the rate of scientific output with a web-based platform that allows researchers to design and run experiments, analyze data, and share results.
Hundreds of thousands of scientists all around the world use Benchling to do research. Whether they are at the world’s largest companies, the top research universities, or working on a startup in a garage, scientists use Benchling for the same reason: to be empowered, not encumbered, by their tools.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.